Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT

Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT

Objective Methotrexate is first-line treatment for many immune-mediated inflammatory diseases. However, it inhibits vaccine-induced immunity – a major concern for this vulnerable group of patients. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster imp...

Full description

Saved in:
Bibliographic Details
Main Authors: Abhishek Abhishek, Nicholas Peckham, Corinna Pade, Joseph M Gibbons, Lucy Cureton, Catherine J Reynolds, Anne Francis, Vicki Barber, Jennifer Williams, Duncan Appelbe, Lucy Eldridge, Patrick Julier, Daniel M Altmann, James Bluett, Tim Brooks, Laura C Coates, Ines Rombach, Amanda Semper, Ashley Otter, Ana M Valdes, Jonathan S Nguyen-Van-Tam, Hywel C Williams, Rosemary J Boyton, Áine McKnight, Jonathan A Cook
Format: Article
Language:English
Published: NIHR Journals Library 2025-04-01
Series:Efficacy and Mechanism Evaluation
Subjects:
covid-19 vaccine
methotrexate rheumatoid arthritis
psoriasis
randomised controlled trial
Online Access:https://doi.org/10.3310/KYTK6537
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.3310/KYTK6537

Similar Items